Who are TALIGLUCERASE ALFA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cerezyme®, Cerezyme® / Imiglucerase, Imiglucerase GZ437843, Vpriv, Cerezyme, Ceredase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/taliglucerase-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TALIGLUCERASE ALFA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TALIGLUCERASE ALFA (TALIGLUCERASE ALFA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC].

marketed Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] glucocerebrosidase Enzyme Live · refreshed every 30 min

Target snapshot

TALIGLUCERASE ALFA (TALIGLUCERASE ALFA). ELELYSO replaces deficient glucocerebrosidase, reducing glucocerebroside accumulation in Gaucher cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TALIGLUCERASE ALFA TARGET	TALIGLUCERASE ALFA		marketed	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]	glucocerebrosidase	2012-01-01
Cerezyme®	Cerezyme®	ISU Abxis Co., Ltd.	marketed	Enzyme replacement therapy	Glucocerebrosidase (β-glucosidase)
Cerezyme® / Imiglucerase	Cerezyme® / Imiglucerase	Sanofi	marketed	Enzyme replacement therapy	Glucocerebrosidase (β-glucosidase)
Imiglucerase GZ437843	Imiglucerase GZ437843	Sanofi	phase 3	Enzyme replacement therapy	Glucocerebrosidase (β-glucosidase)
Vpriv	VELAGLUCERASE ALFA	Shire Human Genetic	marketed	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]		2010-01-01
Cerezyme	IMIGLUCERASE	Sanofi	marketed	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]		1994-01-01
Ceredase	ALGLUCERASE	Sanofi	marketed	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme		1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] class)

· 1 drug in this class
Sanofi · 1 drug in this class
Shire Human Genetic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TALIGLUCERASE ALFA — Competitive Intelligence Brief. https://druglandscape.com/ci/taliglucerase-alfa. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing